A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)

Trial Profile

A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Cediranib; Cisplatin; Fluoropyrimidine derivatives
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Planned end date (14 Oct 2014) added as reported by European Clinical Trials Database record.
    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top